Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Certification | 8 | 2019 | 423 | 2.300 |
Why?
|
Skin Diseases | 14 | 2021 | 1065 | 1.740 |
Why?
|
Dermatology | 6 | 2021 | 870 | 1.490 |
Why?
|
Specialty Boards | 6 | 2019 | 227 | 1.330 |
Why?
|
Skin | 17 | 2022 | 4353 | 0.900 |
Why?
|
Herpes Labialis | 2 | 2020 | 29 | 0.800 |
Why?
|
Antigens, Fungal | 4 | 2010 | 70 | 0.780 |
Why?
|
Cyclobutanes | 2 | 2020 | 59 | 0.770 |
Why?
|
Warts | 4 | 2010 | 68 | 0.770 |
Why?
|
Pemphigus | 1 | 2021 | 103 | 0.760 |
Why?
|
Education, Medical, Continuing | 5 | 2018 | 839 | 0.750 |
Why?
|
Foot Dermatoses | 2 | 2010 | 44 | 0.630 |
Why?
|
Hand Dermatoses | 2 | 2010 | 61 | 0.620 |
Why?
|
Eccrine Glands | 2 | 2013 | 45 | 0.610 |
Why?
|
Hair Follicle | 5 | 2000 | 209 | 0.590 |
Why?
|
Keratinocytes | 5 | 2008 | 797 | 0.580 |
Why?
|
Graft vs Host Reaction | 5 | 1998 | 103 | 0.510 |
Why?
|
Antigens, Viral | 3 | 2005 | 1034 | 0.510 |
Why?
|
Skin Neoplasms | 11 | 2018 | 5662 | 0.500 |
Why?
|
Elastic Tissue | 1 | 2014 | 65 | 0.490 |
Why?
|
Acanthoma | 1 | 2013 | 1 | 0.480 |
Why?
|
Self-Assessment | 1 | 2016 | 390 | 0.470 |
Why?
|
Immunotherapy | 5 | 2017 | 4414 | 0.470 |
Why?
|
Fibroadenoma | 1 | 2013 | 43 | 0.460 |
Why?
|
Erythema | 2 | 2005 | 254 | 0.440 |
Why?
|
Eligibility Determination | 1 | 2016 | 403 | 0.430 |
Why?
|
Fluorescent Antibody Technique, Direct | 2 | 2022 | 69 | 0.420 |
Why?
|
Periodic Acid-Schiff Reaction | 1 | 2010 | 15 | 0.380 |
Why?
|
Keratosis | 2 | 2013 | 81 | 0.370 |
Why?
|
Receptors, Fibronectin | 2 | 2000 | 39 | 0.370 |
Why?
|
Erythema Multiforme | 3 | 1999 | 31 | 0.360 |
Why?
|
Onychomycosis | 1 | 2010 | 47 | 0.360 |
Why?
|
Precancerous Conditions | 2 | 2008 | 971 | 0.350 |
Why?
|
Bone Marrow Transplantation | 8 | 1998 | 2763 | 0.350 |
Why?
|
Candida | 3 | 2010 | 172 | 0.330 |
Why?
|
Photosensitivity Disorders | 2 | 2005 | 78 | 0.320 |
Why?
|
Cystitis, Interstitial | 1 | 2008 | 61 | 0.320 |
Why?
|
Dermatitis | 3 | 2017 | 197 | 0.310 |
Why?
|
Carcinoma in Situ | 4 | 2008 | 802 | 0.310 |
Why?
|
Psoriasis | 5 | 2023 | 898 | 0.300 |
Why?
|
Ribonuclease III | 1 | 2009 | 275 | 0.290 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2008 | 4029 | 0.290 |
Why?
|
Skin Diseases, Infectious | 2 | 2001 | 74 | 0.280 |
Why?
|
Paraffin Embedding | 2 | 2012 | 299 | 0.280 |
Why?
|
Cheilitis | 1 | 2006 | 8 | 0.280 |
Why?
|
Lip Neoplasms | 1 | 2006 | 37 | 0.270 |
Why?
|
Mastocytosis | 1 | 2008 | 160 | 0.270 |
Why?
|
Muscle, Smooth | 2 | 2000 | 933 | 0.270 |
Why?
|
Leg Dermatoses | 1 | 2005 | 20 | 0.270 |
Why?
|
Lymphocytes | 5 | 1998 | 2614 | 0.270 |
Why?
|
Biopsy | 12 | 2017 | 6756 | 0.270 |
Why?
|
Mumps virus | 2 | 2005 | 24 | 0.270 |
Why?
|
Porphyrias | 1 | 2005 | 57 | 0.270 |
Why?
|
Calcinosis | 1 | 2014 | 1497 | 0.260 |
Why?
|
Drug Eruptions | 3 | 2023 | 295 | 0.260 |
Why?
|
Genital Diseases, Male | 1 | 2005 | 83 | 0.260 |
Why?
|
Laboratories | 1 | 2008 | 461 | 0.250 |
Why?
|
Cytodiagnosis | 1 | 2008 | 435 | 0.250 |
Why?
|
Genital Diseases, Female | 1 | 2005 | 197 | 0.240 |
Why?
|
Glucagonoma | 1 | 2003 | 14 | 0.240 |
Why?
|
Overweight | 1 | 2014 | 2366 | 0.220 |
Why?
|
Cystectomy | 2 | 2021 | 682 | 0.220 |
Why?
|
Seminal Vesicles | 1 | 2003 | 101 | 0.220 |
Why?
|
Licensure | 2 | 2013 | 124 | 0.210 |
Why?
|
Bartonella Infections | 1 | 2001 | 22 | 0.210 |
Why?
|
Folliculitis | 1 | 2002 | 28 | 0.210 |
Why?
|
Ampulla of Vater | 2 | 2012 | 141 | 0.210 |
Why?
|
Urinary Bladder | 1 | 2008 | 1171 | 0.200 |
Why?
|
Granuloma Annulare | 1 | 2001 | 28 | 0.200 |
Why?
|
Humans | 84 | 2023 | 742088 | 0.200 |
Why?
|
Eczema | 1 | 2023 | 229 | 0.200 |
Why?
|
Mast Cells | 1 | 2008 | 1544 | 0.190 |
Why?
|
Antifungal Agents | 1 | 2005 | 729 | 0.190 |
Why?
|
Urinary Bladder Neoplasms | 4 | 2021 | 2229 | 0.190 |
Why?
|
Immunohistochemistry | 5 | 2014 | 11363 | 0.190 |
Why?
|
Injections, Intralesional | 4 | 2010 | 276 | 0.180 |
Why?
|
Administration, Topical | 3 | 2020 | 688 | 0.180 |
Why?
|
PUVA Therapy | 2 | 2004 | 98 | 0.180 |
Why?
|
Cryotherapy | 1 | 2001 | 154 | 0.180 |
Why?
|
Bone Marrow | 2 | 2006 | 2941 | 0.180 |
Why?
|
Administration, Cutaneous | 1 | 2022 | 711 | 0.180 |
Why?
|
Myeloproliferative Disorders | 1 | 2006 | 603 | 0.180 |
Why?
|
Indicators and Reagents | 1 | 2000 | 462 | 0.180 |
Why?
|
Clinical Competence | 4 | 2018 | 4681 | 0.180 |
Why?
|
Fibronectins | 2 | 2000 | 723 | 0.180 |
Why?
|
Triazoles | 1 | 2005 | 907 | 0.180 |
Why?
|
Exanthema | 1 | 2023 | 488 | 0.170 |
Why?
|
Graft vs Host Disease | 5 | 2004 | 2951 | 0.160 |
Why?
|
Mycosis Fungoides | 1 | 2000 | 163 | 0.160 |
Why?
|
Proto-Oncogene Proteins | 2 | 2012 | 4553 | 0.160 |
Why?
|
Ethical Analysis | 1 | 2018 | 42 | 0.160 |
Why?
|
Lupus Erythematosus, Discoid | 1 | 2018 | 50 | 0.160 |
Why?
|
Middle Aged | 40 | 2021 | 213127 | 0.160 |
Why?
|
DNA Mutational Analysis | 1 | 2006 | 4187 | 0.150 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 1997 | 176 | 0.150 |
Why?
|
Adjuvants, Immunologic | 2 | 2020 | 1000 | 0.150 |
Why?
|
Male | 51 | 2021 | 349538 | 0.150 |
Why?
|
Langerhans Cells | 1 | 1997 | 173 | 0.150 |
Why?
|
Hair | 1 | 2000 | 483 | 0.150 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2455 | 0.140 |
Why?
|
Lymphocyte Subsets | 1 | 1998 | 315 | 0.140 |
Why?
|
MicroRNAs | 2 | 2012 | 3731 | 0.140 |
Why?
|
Mucins | 1 | 2000 | 564 | 0.140 |
Why?
|
Vitiligo | 1 | 1997 | 90 | 0.140 |
Why?
|
Muscle Neoplasms | 1 | 1997 | 139 | 0.140 |
Why?
|
Keratin-17 | 1 | 2016 | 26 | 0.140 |
Why?
|
Dermatitis, Exfoliative | 1 | 1996 | 28 | 0.140 |
Why?
|
Aged, 80 and over | 20 | 2021 | 57683 | 0.140 |
Why?
|
Amyloidosis | 1 | 2003 | 795 | 0.140 |
Why?
|
Adult | 39 | 2021 | 213712 | 0.130 |
Why?
|
Cyclosporine | 2 | 1996 | 784 | 0.130 |
Why?
|
Adenoma, Sweat Gland | 1 | 1995 | 18 | 0.130 |
Why?
|
Patient Care | 1 | 2021 | 639 | 0.130 |
Why?
|
Integrins | 1 | 2000 | 845 | 0.130 |
Why?
|
Epidermis | 5 | 2003 | 527 | 0.130 |
Why?
|
Transplantation Chimera | 1 | 1998 | 612 | 0.130 |
Why?
|
Interleukin-3 | 1 | 1996 | 441 | 0.130 |
Why?
|
Pancreatic Neoplasms | 3 | 2012 | 5249 | 0.130 |
Why?
|
Hepatitis C | 1 | 2005 | 1582 | 0.130 |
Why?
|
United States | 9 | 2019 | 69693 | 0.120 |
Why?
|
Aged | 30 | 2021 | 162944 | 0.120 |
Why?
|
Biopsy, Needle | 2 | 2014 | 1640 | 0.120 |
Why?
|
Lymphomatoid Papulosis | 1 | 1994 | 16 | 0.120 |
Why?
|
HIV | 1 | 2002 | 1600 | 0.120 |
Why?
|
Necrosis | 3 | 2005 | 1643 | 0.120 |
Why?
|
Fee-for-Service Plans | 1 | 1999 | 694 | 0.110 |
Why?
|
Secondary Prevention | 1 | 2020 | 1520 | 0.110 |
Why?
|
Pain | 2 | 2008 | 4961 | 0.110 |
Why?
|
Pyrimidines | 1 | 2005 | 2933 | 0.110 |
Why?
|
Female | 44 | 2021 | 379592 | 0.110 |
Why?
|
Cytoskeletal Proteins | 1 | 1999 | 1363 | 0.110 |
Why?
|
Graves Disease | 1 | 2014 | 241 | 0.110 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 902 | 0.110 |
Why?
|
Pyoderma Gangrenosum | 1 | 2013 | 75 | 0.110 |
Why?
|
Retrospective Studies | 14 | 2021 | 77098 | 0.110 |
Why?
|
Chronic Disease | 6 | 2018 | 9144 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2016 | 8425 | 0.100 |
Why?
|
Common Bile Duct Neoplasms | 1 | 2012 | 111 | 0.100 |
Why?
|
T-Lymphocytes | 5 | 2000 | 10163 | 0.100 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2017 | 986 | 0.100 |
Why?
|
Adenocarcinoma | 3 | 2016 | 6347 | 0.100 |
Why?
|
Nipples | 1 | 2013 | 216 | 0.100 |
Why?
|
Transforming Growth Factor alpha | 1 | 1991 | 135 | 0.100 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1994 | 654 | 0.100 |
Why?
|
Immunoenzyme Techniques | 5 | 2004 | 1799 | 0.100 |
Why?
|
Intercellular Adhesion Molecule-1 | 3 | 2006 | 1155 | 0.100 |
Why?
|
Silver Staining | 1 | 2010 | 64 | 0.090 |
Why?
|
Autoantibodies | 1 | 1999 | 2036 | 0.090 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2010 | 105 | 0.090 |
Why?
|
Antineoplastic Agents | 4 | 2002 | 13655 | 0.090 |
Why?
|
Nephrogenic Fibrosing Dermopathy | 1 | 2010 | 42 | 0.090 |
Why?
|
Cell Count | 2 | 2008 | 1831 | 0.090 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2010 | 104 | 0.090 |
Why?
|
Breast Diseases | 1 | 2013 | 443 | 0.090 |
Why?
|
Rare Diseases | 1 | 2014 | 554 | 0.090 |
Why?
|
Educational Measurement | 1 | 2016 | 1206 | 0.090 |
Why?
|
Neoplasm Staging | 5 | 2021 | 11001 | 0.090 |
Why?
|
Recurrence | 2 | 2020 | 8333 | 0.090 |
Why?
|
Diagnosis, Differential | 6 | 2005 | 12958 | 0.080 |
Why?
|
Adolescent | 14 | 2017 | 85649 | 0.080 |
Why?
|
Thyroidectomy | 1 | 2014 | 877 | 0.080 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 1989 | 85 | 0.080 |
Why?
|
Mouth Diseases | 2 | 2004 | 239 | 0.080 |
Why?
|
Cell Nucleus | 3 | 2008 | 2968 | 0.080 |
Why?
|
Cystoscopy | 1 | 2008 | 134 | 0.080 |
Why?
|
Double-Blind Method | 3 | 2020 | 12017 | 0.080 |
Why?
|
Radiopharmaceuticals | 1 | 1997 | 2658 | 0.080 |
Why?
|
Pityriasis | 1 | 1987 | 10 | 0.080 |
Why?
|
Reagins | 1 | 1987 | 7 | 0.070 |
Why?
|
Communication | 1 | 2021 | 3728 | 0.070 |
Why?
|
Treatment Outcome | 9 | 2021 | 62966 | 0.070 |
Why?
|
Interferon-gamma | 1 | 1996 | 3199 | 0.070 |
Why?
|
Scalp | 2 | 2000 | 380 | 0.070 |
Why?
|
Syphilis Serodiagnosis | 1 | 1987 | 35 | 0.070 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1998 | 1596 | 0.070 |
Why?
|
ras Proteins | 1 | 2012 | 1060 | 0.070 |
Why?
|
Program Development | 1 | 2013 | 1314 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2015 | 39004 | 0.070 |
Why?
|
Trichophyton | 1 | 2005 | 17 | 0.070 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 1997 | 2524 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2017 | 4414 | 0.070 |
Why?
|
Cytokines | 2 | 2018 | 7317 | 0.070 |
Why?
|
Restriction Mapping | 1 | 2006 | 878 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 1997 | 2522 | 0.060 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1431 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 10943 | 0.060 |
Why?
|
Neoplasms, Vascular Tissue | 1 | 2004 | 35 | 0.060 |
Why?
|
HIV Seropositivity | 1 | 1990 | 970 | 0.060 |
Why?
|
Cytomegalovirus | 1 | 1989 | 730 | 0.060 |
Why?
|
Cell Adhesion Molecules | 1 | 1991 | 1599 | 0.060 |
Why?
|
Polymerase Chain Reaction | 2 | 2006 | 6171 | 0.060 |
Why?
|
Syphilis | 1 | 1987 | 226 | 0.060 |
Why?
|
Weight Gain | 1 | 2014 | 2282 | 0.060 |
Why?
|
Extracellular Matrix | 2 | 2004 | 1740 | 0.060 |
Why?
|
Thrombomodulin | 1 | 2004 | 102 | 0.060 |
Why?
|
Giant Cells | 1 | 2004 | 187 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3691 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5385 | 0.060 |
Why?
|
Ichthyosis | 1 | 2003 | 60 | 0.060 |
Why?
|
Janus Kinase 2 | 1 | 2006 | 527 | 0.060 |
Why?
|
Mass Screening | 1 | 1999 | 5238 | 0.060 |
Why?
|
Gadolinium | 1 | 2008 | 951 | 0.060 |
Why?
|
Cytomegalovirus Infections | 1 | 1989 | 817 | 0.060 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2003 | 96 | 0.060 |
Why?
|
Immunophenotyping | 2 | 1998 | 1866 | 0.050 |
Why?
|
Curriculum | 1 | 2016 | 3589 | 0.050 |
Why?
|
Mumps | 1 | 2003 | 64 | 0.050 |
Why?
|
Sirolimus | 1 | 2010 | 1562 | 0.050 |
Why?
|
Bartonella quintana | 1 | 2001 | 3 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2010 | 14720 | 0.050 |
Why?
|
Primary Health Care | 1 | 1999 | 4551 | 0.050 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2012 | 2028 | 0.050 |
Why?
|
Germany | 2 | 2015 | 860 | 0.050 |
Why?
|
Bartonella henselae | 1 | 2001 | 16 | 0.050 |
Why?
|
Fibrosis | 3 | 2008 | 2026 | 0.050 |
Why?
|
Syndrome | 1 | 2008 | 3248 | 0.050 |
Why?
|
Observer Variation | 1 | 2008 | 2593 | 0.050 |
Why?
|
Tacrolimus | 1 | 2005 | 741 | 0.050 |
Why?
|
Inflammation | 2 | 2018 | 10578 | 0.050 |
Why?
|
Plasma Cells | 2 | 1998 | 592 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2012 | 19862 | 0.050 |
Why?
|
HIV Infections | 2 | 2002 | 16678 | 0.050 |
Why?
|
Point Mutation | 1 | 2006 | 1624 | 0.050 |
Why?
|
Immune Sera | 1 | 2001 | 641 | 0.050 |
Why?
|
Medicare | 1 | 1999 | 6532 | 0.050 |
Why?
|
Alcian Blue | 1 | 2000 | 13 | 0.050 |
Why?
|
Immune Tolerance | 1 | 1989 | 2257 | 0.050 |
Why?
|
DNA, Neoplasm | 1 | 2006 | 1758 | 0.050 |
Why?
|
Integrin alpha1beta1 | 1 | 2000 | 8 | 0.050 |
Why?
|
Candidiasis | 1 | 2003 | 365 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 1999 | 5724 | 0.050 |
Why?
|
Child | 9 | 2005 | 77478 | 0.050 |
Why?
|
Culture Techniques | 1 | 2000 | 554 | 0.050 |
Why?
|
Epithelial Cells | 2 | 2006 | 3678 | 0.050 |
Why?
|
Medical Records | 1 | 2005 | 1413 | 0.050 |
Why?
|
Fibroblasts | 1 | 1990 | 4143 | 0.040 |
Why?
|
Osteoclasts | 1 | 2004 | 729 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2003 | 11039 | 0.040 |
Why?
|
Erythrocytes | 1 | 1988 | 2452 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2013 | 2861 | 0.040 |
Why?
|
Desmoplakins | 1 | 1999 | 62 | 0.040 |
Why?
|
Mississippi | 1 | 1999 | 89 | 0.040 |
Why?
|
Carcinoma | 1 | 1990 | 2374 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2001 | 625 | 0.040 |
Why?
|
Hidradenitis | 1 | 1998 | 3 | 0.040 |
Why?
|
Dermatitis, Atopic | 1 | 2005 | 653 | 0.040 |
Why?
|
Antibodies | 1 | 1987 | 2459 | 0.040 |
Why?
|
Miliaria | 1 | 1998 | 6 | 0.040 |
Why?
|
Mice, Inbred MRL lpr | 1 | 2018 | 159 | 0.040 |
Why?
|
Sweat Gland Diseases | 1 | 1998 | 11 | 0.040 |
Why?
|
Contrast Media | 2 | 2010 | 5295 | 0.040 |
Why?
|
Hypohidrosis | 1 | 1998 | 29 | 0.040 |
Why?
|
Sebaceous Glands | 1 | 1997 | 41 | 0.040 |
Why?
|
Sweat | 1 | 1998 | 49 | 0.040 |
Why?
|
Serine Endopeptidases | 1 | 2003 | 1073 | 0.040 |
Why?
|
Hyperhidrosis | 1 | 1998 | 35 | 0.040 |
Why?
|
Placebos | 2 | 2020 | 1677 | 0.040 |
Why?
|
Technetium Tc 99m Medronate | 1 | 1997 | 134 | 0.040 |
Why?
|
Blister | 1 | 1998 | 85 | 0.040 |
Why?
|
Coloring Agents | 1 | 2000 | 565 | 0.040 |
Why?
|
Hypopigmentation | 1 | 1997 | 41 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2010 | 3639 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2002 | 847 | 0.040 |
Why?
|
Young Adult | 4 | 2017 | 56350 | 0.040 |
Why?
|
Electrolytes | 1 | 1998 | 282 | 0.040 |
Why?
|
Y Chromosome | 1 | 1998 | 206 | 0.040 |
Why?
|
Metaplasia | 1 | 1998 | 313 | 0.040 |
Why?
|
HIV-1 | 1 | 1994 | 6934 | 0.040 |
Why?
|
Mutation | 2 | 2012 | 29717 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2008 | 2145 | 0.040 |
Why?
|
American Medical Association | 1 | 2016 | 65 | 0.040 |
Why?
|
DNA, Bacterial | 1 | 2001 | 1465 | 0.040 |
Why?
|
DNA Methylation | 1 | 2010 | 4282 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2006 | 5062 | 0.030 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2013 | 2410 | 0.030 |
Why?
|
Leukocyte Count | 2 | 1990 | 1583 | 0.030 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 1996 | 189 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2000 | 2505 | 0.030 |
Why?
|
Conjunctivitis | 1 | 1997 | 158 | 0.030 |
Why?
|
Premedication | 1 | 1996 | 257 | 0.030 |
Why?
|
Proteinuria | 1 | 1999 | 657 | 0.030 |
Why?
|
Exocytosis | 1 | 1997 | 353 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 1996 | 6608 | 0.030 |
Why?
|
Cell Differentiation | 3 | 2002 | 11470 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2004 | 1847 | 0.030 |
Why?
|
Diagnostic Errors | 1 | 2002 | 1255 | 0.030 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 1997 | 206 | 0.030 |
Why?
|
Antibodies, Monoclonal | 3 | 2000 | 9274 | 0.030 |
Why?
|
Pilot Projects | 2 | 2001 | 8297 | 0.030 |
Why?
|
Rats, Inbred ACI | 1 | 1994 | 44 | 0.030 |
Why?
|
Antigens, CD1 | 1 | 1997 | 437 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2006 | 4801 | 0.030 |
Why?
|
Acute Disease | 2 | 1998 | 7141 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2006 | 3038 | 0.030 |
Why?
|
Cyclosporins | 1 | 1994 | 220 | 0.030 |
Why?
|
HIV Core Protein p24 | 1 | 1994 | 256 | 0.030 |
Why?
|
Connective Tissue Diseases | 1 | 1997 | 264 | 0.030 |
Why?
|
Herpesvirus 1, Human | 1 | 2020 | 742 | 0.030 |
Why?
|
BCG Vaccine | 1 | 1997 | 367 | 0.030 |
Why?
|
Antigens, CD | 2 | 1998 | 4024 | 0.030 |
Why?
|
HLA-DR Antigens | 1 | 1996 | 644 | 0.030 |
Why?
|
Mouth Mucosa | 1 | 1997 | 434 | 0.030 |
Why?
|
Coma | 1 | 1998 | 475 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2006 | 2542 | 0.030 |
Why?
|
Prostatectomy | 1 | 2003 | 1871 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 1998 | 1950 | 0.030 |
Why?
|
Demography | 1 | 1999 | 1650 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15530 | 0.030 |
Why?
|
Fumarates | 1 | 1994 | 132 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 1998 | 4379 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 1997 | 2027 | 0.030 |
Why?
|
Cytoplasm | 1 | 1998 | 1539 | 0.030 |
Why?
|
Phenotype | 2 | 2023 | 16331 | 0.030 |
Why?
|
Preoperative Period | 1 | 2015 | 546 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6534 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2000 | 3139 | 0.030 |
Why?
|
Interleukin-1 | 1 | 1996 | 1262 | 0.030 |
Why?
|
Child, Preschool | 3 | 2003 | 40955 | 0.030 |
Why?
|
Virus Activation | 1 | 1994 | 319 | 0.030 |
Why?
|
Rats, Inbred Lew | 1 | 1994 | 1161 | 0.030 |
Why?
|
Physical Examination | 1 | 1999 | 1239 | 0.030 |
Why?
|
Epithelium | 1 | 1997 | 1680 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2005 | 4147 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20086 | 0.030 |
Why?
|
Eosinophils | 1 | 1997 | 953 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4929 | 0.030 |
Why?
|
Edema | 1 | 1996 | 790 | 0.030 |
Why?
|
Whole-Body Irradiation | 1 | 1992 | 449 | 0.030 |
Why?
|
Amsacrine | 1 | 1991 | 18 | 0.020 |
Why?
|
Diabetes Complications | 1 | 1999 | 1359 | 0.020 |
Why?
|
Drug Resistance | 1 | 2017 | 1608 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 1998 | 2876 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2017 | 900 | 0.020 |
Why?
|
Survival Rate | 2 | 2015 | 12773 | 0.020 |
Why?
|
Carcinoma, Pancreatic Ductal | 2 | 2012 | 1631 | 0.020 |
Why?
|
Endocrine System Diseases | 1 | 2013 | 248 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 1996 | 2271 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 1999 | 1737 | 0.020 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 1991 | 65 | 0.020 |
Why?
|
Daunorubicin | 1 | 1991 | 149 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2001 | 2714 | 0.020 |
Why?
|
Formaldehyde | 1 | 2012 | 353 | 0.020 |
Why?
|
Genome, Viral | 1 | 1994 | 667 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 1990 | 6754 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 1998 | 1780 | 0.020 |
Why?
|
Bilirubin | 1 | 1992 | 424 | 0.020 |
Why?
|
Metaphase | 1 | 1990 | 151 | 0.020 |
Why?
|
Ploidies | 1 | 1990 | 281 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2948 | 0.020 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 1991 | 378 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 1998 | 2133 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 1998 | 1178 | 0.020 |
Why?
|
Cytarabine | 1 | 1991 | 684 | 0.020 |
Why?
|
Tissue Donors | 1 | 1998 | 2205 | 0.020 |
Why?
|
Histocytochemistry | 1 | 1989 | 718 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 1996 | 20774 | 0.020 |
Why?
|
Time Factors | 3 | 2015 | 40054 | 0.020 |
Why?
|
Endothelium | 1 | 1991 | 778 | 0.020 |
Why?
|
DNA, Viral | 1 | 1994 | 2224 | 0.020 |
Why?
|
Bone Marrow Diseases | 1 | 1989 | 230 | 0.020 |
Why?
|
Pancreatectomy | 1 | 2012 | 802 | 0.020 |
Why?
|
Prospective Studies | 4 | 2003 | 53187 | 0.020 |
Why?
|
Leukemia, Myeloid | 1 | 1991 | 705 | 0.020 |
Why?
|
Lipids | 1 | 1999 | 3302 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3612 | 0.020 |
Why?
|
Ultrasonography | 1 | 2000 | 5978 | 0.020 |
Why?
|
Single-Blind Method | 1 | 1990 | 1589 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 1998 | 11472 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1997 | 2948 | 0.020 |
Why?
|
Feces | 1 | 1992 | 1394 | 0.020 |
Why?
|
Gadolinium DTPA | 1 | 2010 | 836 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 1998 | 4554 | 0.020 |
Why?
|
RNA, Viral | 1 | 1994 | 2899 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 1998 | 8621 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 1994 | 4771 | 0.020 |
Why?
|
Ointments | 1 | 2005 | 59 | 0.020 |
Why?
|
Palliative Care | 1 | 2021 | 3478 | 0.020 |
Why?
|
Fractures, Bone | 1 | 1997 | 1945 | 0.020 |
Why?
|
Animals | 3 | 2018 | 168561 | 0.020 |
Why?
|
Pancreas | 1 | 2012 | 1684 | 0.020 |
Why?
|
Prognosis | 3 | 2015 | 29010 | 0.020 |
Why?
|
Pancreatitis | 1 | 2012 | 1090 | 0.020 |
Why?
|
Gene Frequency | 1 | 2012 | 3587 | 0.020 |
Why?
|
Lymphoma | 1 | 1994 | 1873 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1683 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 1998 | 4664 | 0.020 |
Why?
|
Granuloma, Pyogenic | 1 | 2004 | 48 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2010 | 1606 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 1998 | 4438 | 0.020 |
Why?
|
Autopsy | 1 | 2008 | 1006 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2008 | 2335 | 0.010 |
Why?
|
Cell Division | 1 | 1991 | 4564 | 0.010 |
Why?
|
Quality of Health Care | 1 | 1999 | 4369 | 0.010 |
Why?
|
Blotting, Western | 1 | 1991 | 5180 | 0.010 |
Why?
|
Phagocytosis | 1 | 1988 | 1538 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 2012 | 12242 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2003 | 428 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 2004 | 657 | 0.010 |
Why?
|
T-Lymphocyte Subsets | 1 | 1990 | 1837 | 0.010 |
Why?
|
Hemangiosarcoma | 1 | 2004 | 236 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2008 | 15108 | 0.010 |
Why?
|
Blood Vessels | 1 | 2008 | 1124 | 0.010 |
Why?
|
Kallikreins | 1 | 2003 | 258 | 0.010 |
Why?
|
Sarcoma, Kaposi | 1 | 2004 | 370 | 0.010 |
Why?
|
Sunlight | 1 | 2003 | 325 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 1999 | 7276 | 0.010 |
Why?
|
Quality Improvement | 1 | 2016 | 3738 | 0.010 |
Why?
|
Leukemia | 1 | 1989 | 1507 | 0.010 |
Why?
|
Risk Assessment | 1 | 2003 | 23320 | 0.010 |
Why?
|
Ossification, Heterotopic | 1 | 2004 | 239 | 0.010 |
Why?
|
von Willebrand Factor | 1 | 2004 | 668 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1996 | 3497 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1990 | 5975 | 0.010 |
Why?
|
Adenoma | 1 | 1990 | 2168 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 1998 | 9185 | 0.010 |
Why?
|
Hemangioma | 1 | 2004 | 737 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15056 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2010 | 5867 | 0.010 |
Why?
|
Myelodysplastic Syndromes | 1 | 1988 | 1351 | 0.010 |
Why?
|
Rats | 1 | 1994 | 24265 | 0.010 |
Why?
|
Models, Biological | 1 | 1994 | 9581 | 0.010 |
Why?
|
Genotype | 1 | 2012 | 12946 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1996 | 12071 | 0.010 |
Why?
|
DNA | 1 | 1990 | 7289 | 0.010 |
Why?
|
Ifosfamide | 1 | 1996 | 225 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 9410 | 0.010 |
Why?
|
Liver | 2 | 2008 | 7470 | 0.010 |
Why?
|
Smoking | 1 | 2012 | 8969 | 0.010 |
Why?
|
Etoposide | 1 | 1996 | 637 | 0.010 |
Why?
|
Neoplasms | 2 | 2013 | 21596 | 0.010 |
Why?
|
Myocardium | 1 | 2008 | 4775 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2004 | 1780 | 0.010 |
Why?
|
Flushing | 1 | 1994 | 49 | 0.010 |
Why?
|
Carboplatin | 1 | 1996 | 799 | 0.010 |
Why?
|
Joints | 1 | 1994 | 326 | 0.010 |
Why?
|
Pregnancy | 1 | 2013 | 29087 | 0.010 |
Why?
|
Mice | 1 | 2018 | 81045 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2004 | 2536 | 0.010 |
Why?
|
Hepatic Veins | 1 | 1991 | 112 | 0.010 |
Why?
|
Drug Combinations | 1 | 1994 | 1961 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2004 | 4246 | 0.010 |
Why?
|
Remission Induction | 1 | 1994 | 2384 | 0.010 |
Why?
|
Abdominal Pain | 1 | 1994 | 1059 | 0.000 |
Why?
|
Diarrhea | 1 | 1994 | 1343 | 0.000 |
Why?
|
Staining and Labeling | 1 | 1991 | 1099 | 0.000 |
Why?
|
Quality of Life | 1 | 2004 | 12730 | 0.000 |
Why?
|
Cohort Studies | 1 | 2005 | 40450 | 0.000 |
Why?
|
Disease Progression | 1 | 1997 | 13256 | 0.000 |
Why?
|